Japanese Study Identifies Survival Markers in Rare Pancreatic Cancer
A 387-patient study links surgery, chemotherapy, and tumor markers to survival in rare pancreatic acinar cell carcinoma.
Summary
A nationwide Japanese study examined 387 patients with pancreatic acinar cell carcinoma, a rare pancreatic cancer. Patients who underwent surgery had a five-year survival rate of 55.3%, compared with 4.5% among those whose disease could not be surgically removed. These groups likely differed substantially, so the comparison does not prove surgery caused the survival advantage. Older age and more advanced cancer were also linked to shorter survival. Among patients without surgery, FOLFIRINOX chemotherapy was associated with longer survival. An additional review of tumor samples identified markers linked to poorer outcomes, including a high proportion of actively dividing cancer cells. The findings could help specialists discuss prognosis and design future studies, but they do not establish which treatment works best. This summary is based on the abstract only.
Detailed Summary
Pancreatic acinar cell carcinoma is a rare pancreatic cancer with limited evidence to guide treatment and prognosis. A nationwide Japanese study provides a clearer picture of survival patterns and tumor features associated with poorer outcomes. Its findings may help clinicians refine discussions about prognosis and identify priorities for future trials.
Researchers collected records from 387 patients treated at 85 Japanese referral centers between 2000 and 2022. The median age was 64 years, and 71.3% were men. Surgery was performed in 260 patients; 127 had disease that was not resectable. Specialists also centrally reviewed 108 tumor specimens to assess microscopic characteristics and markers of cancer cell growth.
Among patients who underwent surgery, median survival was 2,610 days, with 55.3% alive at five years. Among those without surgery, median survival was 415 days, and five-year survival was 4.5%. Older age, more advanced cancer, and no surgery were independently associated with shorter survival. These comparisons do not establish that surgery alone caused the survival difference.
In patients without surgery, receiving FOLFIRINOX chemotherapy was associated with longer survival, while receiving no chemotherapy was associated with worse outcomes. Tumors with alpha-fetoprotein staining or a Ki-67 growth marker of at least 30% were associated with poorer survival. These findings support further evaluation of tumor markers for risk assessment and chemotherapy options for patients whose cancers cannot be surgically removed.
However, this observational study cannot prove treatment benefits because patients selected for surgery or particular chemotherapy regimens may differ substantially from other patients. Care also changed over the long enrollment period, and centralized tumor review covered only a subset. The abstract does not report treatment effect sizes or detailed adjustment methods. This summary is based on the abstract only; individual treatment decisions still require specialist assessment of disease extent, overall health, and available evidence and patient preferences.
Key Findings
- Five-year survival was 55.3% after resection versus 4.5% without resection; differences in disease severity limit direct treatment comparisons.
- Older age, advanced stage, and non-resection were independently associated with shorter overall survival.
- Among patients without surgery, FOLFIRINOX was associated with longer survival; absence of chemotherapy was associated with worse prognosis.
- Tumor alpha-fetoprotein positivity and Ki-67 of at least 30% independently predicted poorer survival in the pathology analysis.
- These associations may inform specialist prognosis discussions but do not establish the best treatment for an individual patient.
Methodology
This multicenter observational study collected data on 387 patients with pathologically diagnosed pancreatic acinar cell carcinoma treated at 85 Japanese tertiary referral centers between 2000 and 2022. Centralized pathology review assessed 108 specimens from 41 institutions, and Cox proportional hazards models examined associations with overall survival.
Study Limitations
This summary is based on the abstract only, which does not provide hazard ratios, confidence intervals, or complete adjustment details. Nonrandomized treatment selection, differences in disease stage, and changes in care across 2000–2022 limit causal interpretation. Centralized pathology covered only a subset, and findings from Japanese tertiary centers may not generalize to all settings.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
